NO20011409L - Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer - Google Patents

Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer

Info

Publication number
NO20011409L
NO20011409L NO20011409A NO20011409A NO20011409L NO 20011409 L NO20011409 L NO 20011409L NO 20011409 A NO20011409 A NO 20011409A NO 20011409 A NO20011409 A NO 20011409A NO 20011409 L NO20011409 L NO 20011409L
Authority
NO
Norway
Prior art keywords
microadenomas
adhd
parkinson
pharmaceuticals
disease
Prior art date
Application number
NO20011409A
Other languages
English (en)
Other versions
NO20011409D0 (no
Inventor
Elisa Rose Jackson
Stafford Mclean
Stevin Howard Zorn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20011409D0 publication Critical patent/NO20011409D0/no
Publication of NO20011409L publication Critical patent/NO20011409L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20011409A 1998-09-21 2001-03-20 Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer NO20011409L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12
PCT/IB1999/001503 WO2000016777A1 (en) 1998-09-21 1999-09-03 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas

Publications (2)

Publication Number Publication Date
NO20011409D0 NO20011409D0 (no) 2001-03-20
NO20011409L true NO20011409L (no) 2001-03-28

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011409A NO20011409L (no) 1998-09-21 2001-03-20 Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer

Country Status (38)

Country Link
US (2) US6300329B1 (no)
EP (1) EP1115402A1 (no)
JP (1) JP2002526448A (no)
KR (3) KR100468340B1 (no)
CN (1) CN1319013A (no)
AP (1) AP1456A (no)
AR (1) AR029739A1 (no)
AU (1) AU760230B2 (no)
BG (1) BG105445A (no)
BR (1) BR9913975A (no)
CA (1) CA2344670A1 (no)
CO (1) CO5140075A1 (no)
CZ (1) CZ20011006A3 (no)
DZ (1) DZ2894A1 (no)
EA (2) EA200100204A1 (no)
EE (1) EE200100179A (no)
GE (1) GEP20033081B (no)
GT (1) GT199900154A (no)
HN (1) HN1999000146A (no)
HR (1) HRP20010209A2 (no)
HU (1) HUP0103691A3 (no)
ID (1) ID28028A (no)
IL (2) IL141507A0 (no)
IS (1) IS5852A (no)
MA (1) MA26690A1 (no)
MY (1) MY127939A (no)
NO (1) NO20011409L (no)
NZ (1) NZ509855A (no)
OA (1) OA11653A (no)
PA (1) PA8482001A1 (no)
PE (1) PE20001084A1 (no)
PL (1) PL346904A1 (no)
SK (1) SK3592001A3 (no)
TN (1) TNSN99177A1 (no)
TR (2) TR200101357T2 (no)
TW (1) TW518225B (no)
WO (1) WO2000016777A1 (no)
YU (1) YU21701A (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
WO2002102988A2 (en) * 2001-06-18 2002-12-27 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
TW200800306A (en) 2005-09-12 2008-01-01 Wyeth Corp Sustained-release formulation and uses thereof
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX19222A (es) * 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
WO1992000075A1 (en) * 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
ES2163506T3 (es) * 1994-06-14 2002-02-01 Pfizer Derivados de bencimidazolona con actividad dopaminergica central.
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
ID28028A (id) 2001-05-03
PA8482001A1 (es) 2000-05-24
AR029739A1 (es) 2003-07-16
IL164839A0 (en) 2005-12-18
CO5140075A1 (es) 2002-03-22
KR100468340B1 (ko) 2005-01-27
PL346904A1 (en) 2002-03-11
HUP0103691A2 (hu) 2002-02-28
TR200402083T2 (tr) 2004-10-21
MY127939A (en) 2007-01-31
CA2344670A1 (en) 2000-03-30
NO20011409D0 (no) 2001-03-20
SK3592001A3 (en) 2001-12-03
TW518225B (en) 2003-01-21
OA11653A (en) 2004-12-08
EA200100204A1 (ru) 2001-08-27
WO2000016777A1 (en) 2000-03-30
YU21701A (sh) 2004-07-15
CN1319013A (zh) 2001-10-24
TNSN99177A1 (fr) 2005-11-10
PE20001084A1 (es) 2000-10-18
AU760230B2 (en) 2003-05-08
US6300329B1 (en) 2001-10-09
CZ20011006A3 (cs) 2001-09-12
EE200100179A (et) 2002-10-15
KR20030088512A (ko) 2003-11-19
AP2001002102A0 (en) 2001-03-31
US20010034347A1 (en) 2001-10-25
EA200301063A1 (ru) 2004-12-30
HRP20010209A2 (en) 2002-04-30
HN1999000146A (es) 2000-11-11
NZ509855A (en) 2003-04-29
AU5383199A (en) 2000-04-10
DZ2894A1 (fr) 2003-12-15
BG105445A (en) 2001-12-29
GT199900154A (es) 2001-03-06
IS5852A (is) 2001-02-20
KR20040054752A (ko) 2004-06-25
GEP20033081B (en) 2003-10-27
US6608064B2 (en) 2003-08-19
TR200101357T2 (tr) 2001-08-21
MA26690A1 (fr) 2004-12-20
IL141507A0 (en) 2002-03-10
EP1115402A1 (en) 2001-07-18
JP2002526448A (ja) 2002-08-20
BR9913975A (pt) 2001-06-19
HUP0103691A3 (en) 2003-01-28
AP1456A (en) 2005-09-30
KR20010075222A (ko) 2001-08-09

Similar Documents

Publication Publication Date Title
NO20011409L (no) Farmasöytiske midler for behandling av Parkinsonssykdom, ADHD og mikroadenomer
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
NO20063000L (no) Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav.
NO20004098D0 (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
GB2367060B (en) Alzheimer's disease secretase,app substrates therefor,and uses therefor
WO1999048482A3 (en) Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
NO20006630L (no) Farmasöytisk sammensetning for behandlingen av diabetes
NO20001001D0 (no) Poly (ADP-ribose) polymerase ("PARP") inhibitorer, fremgangsmõte og farmasøytiske sammensetninger for behandling av neurale og kardiovaskulære vevskader
LTC0914118I2 (lt) Pakeistieji 3,5-difenil-1,2,4-triazolai ir jų panaudojimas farmaciniais metalų chelatoriais
NO20004915L (no) Transdermalt terapeutisk system som inneholder en D2-agonist og som tilveiebringes for behandling av Parkinsons sykdom og en fremgangsmÕte for dets fremstilling
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
NO20015542L (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20012963L (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20005179D0 (no) Medikament behandling
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
DK1202996T3 (da) Titanforbindelser, fremstilling og anvendelse heraf
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita'disinfettante e cicatrizzante, e biopolimeri iodurati cosi' ottenuti.
NO20001909L (no) FremgangsmÕte og anlegg for fremstilling av 1,2-dikloretan
DE69604071D1 (de) Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
ZA200102029B (en) Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas.
HK1039574A1 (zh) 治療帕金森氏病、adhd和微腺瘤的藥物試劑

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application